Senescent cells: an emerging target for diseases of ageing. Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R., Marquess, D., Dananberg, J., & van Deursen, J. M. Nature Reviews Drug Discovery, 16(10):718–735, October, 2017. Number: 10 Publisher: Nature Publishing Group![Senescent cells: an emerging target for diseases of ageing [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Cellular senescence is a tumour-suppressive fate by which damaged cells permanently withdraw from the cell cycle and acquire a distinct secretome.A variety of age-related diseases as well as beneficial, normal processes have been linked to either senescence arrest or to factors released in the senescent cell (SNC) secretome in recent years.Evidence for a potential role of SNCs in major diseases, including osteoarthritis, atherosclerosis and cancer, has sparked interest in the development of senotherapies, treatments aimed at neutralizing the disease-causing features of SNCs.One main senotherapeutic strategy is senolysis in which drugs (senolytics) are used to specifically and efficiently kill SNCs. First-generation senolytics generally act by inhibiting pro-survival adaptations that SNCs use to resist apoptosis and have shown efficacy against atherosclerosis, osteoarthritis and other age-related diseases.Inhibition of the senescence-associated secretory phenotype (SASP) may be another useful senotherapy, but — in contrast to senolysis — this would likely require continuous dosing, whereas SNC killing could be carried out intermittently.Senotherapy is a promising new approach to treating age-related diseases, but successfully translating this to the clinic will require new methods for evaluating SNC burden in humans, a clear mechanistic understanding of the link between senescence and disease and proof that senotherapy is safe.
@article{childs_senescent_2017,
title = {Senescent cells: an emerging target for diseases of ageing},
volume = {16},
copyright = {2017 Springer Nature Limited},
issn = {1474-1784},
shorttitle = {Senescent cells},
url = {https://www.nature.com/articles/nrd.2017.116},
doi = {10.1038/nrd.2017.116},
abstract = {Cellular senescence is a tumour-suppressive fate by which damaged cells permanently withdraw from the cell cycle and acquire a distinct secretome.A variety of age-related diseases as well as beneficial, normal processes have been linked to either senescence arrest or to factors released in the senescent cell (SNC) secretome in recent years.Evidence for a potential role of SNCs in major diseases, including osteoarthritis, atherosclerosis and cancer, has sparked interest in the development of senotherapies, treatments aimed at neutralizing the disease-causing features of SNCs.One main senotherapeutic strategy is senolysis in which drugs (senolytics) are used to specifically and efficiently kill SNCs. First-generation senolytics generally act by inhibiting pro-survival adaptations that SNCs use to resist apoptosis and have shown efficacy against atherosclerosis, osteoarthritis and other age-related diseases.Inhibition of the senescence-associated secretory phenotype (SASP) may be another useful senotherapy, but — in contrast to senolysis — this would likely require continuous dosing, whereas SNC killing could be carried out intermittently.Senotherapy is a promising new approach to treating age-related diseases, but successfully translating this to the clinic will require new methods for evaluating SNC burden in humans, a clear mechanistic understanding of the link between senescence and disease and proof that senotherapy is safe.},
language = {en},
number = {10},
urldate = {2023-08-17},
journal = {Nature Reviews Drug Discovery},
author = {Childs, Bennett G. and Gluscevic, Martina and Baker, Darren J. and Laberge, Remi-Martin and Marquess, Dan and Dananberg, Jamie and van Deursen, Jan M.},
month = oct,
year = {2017},
note = {Number: 10
Publisher: Nature Publishing Group},
keywords = {Ageing, Drug discovery, Senescence},
pages = {718--735},
}
Downloads: 0
{"_id":"oizJFrYzWuSLjg72n","bibbaseid":"childs-gluscevic-baker-laberge-marquess-dananberg-vandeursen-senescentcellsanemergingtargetfordiseasesofageing-2017","author_short":["Childs, B. G.","Gluscevic, M.","Baker, D. J.","Laberge, R.","Marquess, D.","Dananberg, J.","van Deursen, J. M."],"bibdata":{"bibtype":"article","type":"article","title":"Senescent cells: an emerging target for diseases of ageing","volume":"16","copyright":"2017 Springer Nature Limited","issn":"1474-1784","shorttitle":"Senescent cells","url":"https://www.nature.com/articles/nrd.2017.116","doi":"10.1038/nrd.2017.116","abstract":"Cellular senescence is a tumour-suppressive fate by which damaged cells permanently withdraw from the cell cycle and acquire a distinct secretome.A variety of age-related diseases as well as beneficial, normal processes have been linked to either senescence arrest or to factors released in the senescent cell (SNC) secretome in recent years.Evidence for a potential role of SNCs in major diseases, including osteoarthritis, atherosclerosis and cancer, has sparked interest in the development of senotherapies, treatments aimed at neutralizing the disease-causing features of SNCs.One main senotherapeutic strategy is senolysis in which drugs (senolytics) are used to specifically and efficiently kill SNCs. First-generation senolytics generally act by inhibiting pro-survival adaptations that SNCs use to resist apoptosis and have shown efficacy against atherosclerosis, osteoarthritis and other age-related diseases.Inhibition of the senescence-associated secretory phenotype (SASP) may be another useful senotherapy, but — in contrast to senolysis — this would likely require continuous dosing, whereas SNC killing could be carried out intermittently.Senotherapy is a promising new approach to treating age-related diseases, but successfully translating this to the clinic will require new methods for evaluating SNC burden in humans, a clear mechanistic understanding of the link between senescence and disease and proof that senotherapy is safe.","language":"en","number":"10","urldate":"2023-08-17","journal":"Nature Reviews Drug Discovery","author":[{"propositions":[],"lastnames":["Childs"],"firstnames":["Bennett","G."],"suffixes":[]},{"propositions":[],"lastnames":["Gluscevic"],"firstnames":["Martina"],"suffixes":[]},{"propositions":[],"lastnames":["Baker"],"firstnames":["Darren","J."],"suffixes":[]},{"propositions":[],"lastnames":["Laberge"],"firstnames":["Remi-Martin"],"suffixes":[]},{"propositions":[],"lastnames":["Marquess"],"firstnames":["Dan"],"suffixes":[]},{"propositions":[],"lastnames":["Dananberg"],"firstnames":["Jamie"],"suffixes":[]},{"propositions":["van"],"lastnames":["Deursen"],"firstnames":["Jan","M."],"suffixes":[]}],"month":"October","year":"2017","note":"Number: 10 Publisher: Nature Publishing Group","keywords":"Ageing, Drug discovery, Senescence","pages":"718–735","bibtex":"@article{childs_senescent_2017,\n\ttitle = {Senescent cells: an emerging target for diseases of ageing},\n\tvolume = {16},\n\tcopyright = {2017 Springer Nature Limited},\n\tissn = {1474-1784},\n\tshorttitle = {Senescent cells},\n\turl = {https://www.nature.com/articles/nrd.2017.116},\n\tdoi = {10.1038/nrd.2017.116},\n\tabstract = {Cellular senescence is a tumour-suppressive fate by which damaged cells permanently withdraw from the cell cycle and acquire a distinct secretome.A variety of age-related diseases as well as beneficial, normal processes have been linked to either senescence arrest or to factors released in the senescent cell (SNC) secretome in recent years.Evidence for a potential role of SNCs in major diseases, including osteoarthritis, atherosclerosis and cancer, has sparked interest in the development of senotherapies, treatments aimed at neutralizing the disease-causing features of SNCs.One main senotherapeutic strategy is senolysis in which drugs (senolytics) are used to specifically and efficiently kill SNCs. First-generation senolytics generally act by inhibiting pro-survival adaptations that SNCs use to resist apoptosis and have shown efficacy against atherosclerosis, osteoarthritis and other age-related diseases.Inhibition of the senescence-associated secretory phenotype (SASP) may be another useful senotherapy, but — in contrast to senolysis — this would likely require continuous dosing, whereas SNC killing could be carried out intermittently.Senotherapy is a promising new approach to treating age-related diseases, but successfully translating this to the clinic will require new methods for evaluating SNC burden in humans, a clear mechanistic understanding of the link between senescence and disease and proof that senotherapy is safe.},\n\tlanguage = {en},\n\tnumber = {10},\n\turldate = {2023-08-17},\n\tjournal = {Nature Reviews Drug Discovery},\n\tauthor = {Childs, Bennett G. and Gluscevic, Martina and Baker, Darren J. and Laberge, Remi-Martin and Marquess, Dan and Dananberg, Jamie and van Deursen, Jan M.},\n\tmonth = oct,\n\tyear = {2017},\n\tnote = {Number: 10\nPublisher: Nature Publishing Group},\n\tkeywords = {Ageing, Drug discovery, Senescence},\n\tpages = {718--735},\n}\n\n","author_short":["Childs, B. G.","Gluscevic, M.","Baker, D. J.","Laberge, R.","Marquess, D.","Dananberg, J.","van Deursen, J. M."],"key":"childs_senescent_2017","id":"childs_senescent_2017","bibbaseid":"childs-gluscevic-baker-laberge-marquess-dananberg-vandeursen-senescentcellsanemergingtargetfordiseasesofageing-2017","role":"author","urls":{"Paper":"https://www.nature.com/articles/nrd.2017.116"},"keyword":["Ageing","Drug discovery","Senescence"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/qingyuhms","dataSources":["uJZG8wcPfTAfBw67Z"],"keywords":["ageing","drug discovery","senescence"],"search_terms":["senescent","cells","emerging","target","diseases","ageing","childs","gluscevic","baker","laberge","marquess","dananberg","van deursen"],"title":"Senescent cells: an emerging target for diseases of ageing","year":2017}